glp-1 agonist clinical trials Real-World Evidence for Receptor Agonists Across the CKD Spectrum – AJKD Blog Issue 42: GLP-1 RA Drug

F., Leech, C

Boney CM, Verma A, Tucker R, Vohr BR

Moreover, there was no significant change in urine SI with respect to calcium phosphate (0.740.99 to 0.630.58) or uric acid (1.091.07 to 1.001.12) in the GLP group (Table 3)

Interestingly, a triple GLP-1/GIP/glucagon receptor agonist was found to have neuroprotective effects on a transgenic mouse model of Alzheimers disease, as drug treatment increased neurogenesis and reversed memory deficit

Blood-brain glucose transfer in Alzheimer's disease: Effect of GLP-1 analog treatment

Additional studies, including randomised controlled trials, will be needed to corroborate our findings and to explore the full therapeutic potential of the GLP-1 receptor agonist-SGLT-2 inhibitor combination among patients with type 2 diabetes